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According to Professor Gutgesell, sudden and unexpected
deaths in young athletes and celebrities elicit intense media
coverage, often accompanied by the questions, ‘‘Why did he
die?’’ and ‘‘Why could not this have been prevented?’’ (1).
Interestingly, these two important questions are also asked
by the relatives of patients with epilepsy who die suddenly.
In the field of epilepsy, how can we elucidate these issues?
Regarding the first question, in the vernacular of the
epilepsy world, the patient suffered what is called ‘‘sudden
unexplained death in epilepsy’’ (SUDEP). SUDEP is a leading
cause of mortality in patients with epilepsy (2) and is defined
as sudden, unexpected, witnessed or unwitnessed, non-
traumatic, and non-drowning deaths in patients with epi-
lepsy. It occurs with or without evidence of a seizure,
excluding documented status epilepticus, when the post-
mortem examination does not reveal a toxicological or
anatomical cause of death (3). The reported incidence of
SUDEP is variable, largely due to the differences in patient
populations, study designs, and the criteria used for defining
the condition (2). In fact, results from a US population-based
study indicate that the risk of sudden death in people with
epilepsy is estimated to be as much as 20 times higher than
that of the general population (4). In general terms, SUDEP is
responsible for 7.5% to 17% of all deaths in patients with
epilepsy and has an incidence between 15500 and 151,000
patient-years among affected adults (5). Concerning risk
factors, a number of associated factors have been reported,
but the results are not consistent between studies. To date,
several studies have identified factors that potentially
correlate with an elevated risk of SUDEP, such as the
refractoriness of the epileptic condition, presence of general-
ized tonic-clonic seizures, early onset of epilepsy, antiepileptic
medication (polytherapy with antiepileptic drugs), young age,
and duration of the seizure disorder (2,6,7). Although the
cause of SUDEP is still unknown, one of the main mechan-
isms of SUDEP is autonomic dysregulation (i.e., cardiac
abnormalities during and between seizures) (6-8).
To address the second question (‘‘Why could not this have
been prevented?’’), although progress has been made relating
to SUDEP over the last decade, it remains somewhat of a
‘black box’ phenomenon (6). Thus, predicting and preventing
SUDEP are challenging tasks (6). Although we still are unable
to prevent the onset of epilepsy or to reverse an established
clinical picture, preventive measures in clinical practice have
been proposed to minimize the occurrence of SUDEP: 1) good
seizure control; 2) stress reduction; 3) participation in physical
activities and sports; 4) supervision at night; 5) educating
family members regarding cardiopulmonary resuscitation
(CPR) techniques and the basics of defibrillator use; and 6)
dietary management (i.e., omega-3 supplementation) (9).
However, we agree with Shorvon and Tomson (10) that
because there are no data on the effectiveness of any particular
clinical strategy, these suggestions are merely speculative.
However, based on the reported evidence, we believe that
reducing the occurrence of tonic-clonic seizures, exercising
caution when changing antiepileptic drugs, and improving
post-ictal surveillance are likely to be beneficial (10).
From a cardiovascular perspective and because themechan-
ism for the occurrence of SUDEP in people with uncontrolled
seizures could be of cardiac origin, (6-8) it seems obvious that a
true convergence of clinical neurology and cardiology should
be adopted to attempt to minimize the occurrence of sudden
cardiac death in individuals with epilepsy. Thus, some
primary and secondary preventive measures should be
evaluated in people with refractory epilepsy.
Similar to individuals in the general population, all people
with epilepsy should regularly take part in important
primary preventive measures. We must remember that
because sudden cardiac arrest is often linked with coronary
artery disease, the same factors that put a patient at risk of
coronary artery disease may also put them at risk for sudden
cardiac arrest. These factors include a family history of
coronary artery disease, smoking, high blood pressure, high
blood cholesterol, obesity, diabetes, and a sedentary lifestyle.
Concerning secondary preventive measures, individuals
with epilepsy that are also at a high risk for SUDEP should
receive additional tests. Because identifying cardiovascular
abnormalities may help prevent episodes of cardiac arrest,
the recommended tests include blood tests (lipid, enzy-
matic, hormone, and electrolyte profiling) and electrocar-
diography. In addition, imaging tests are suggested to
screen for cardiac dysfunction, such as chest X-rays, nuclear
scans, and echocardiograms.
Email: scorza.nexp@epm.br
Tel.: 55 11 5549 2064
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(1):1-2 DOI:10.6061/clinics/2012(01)01
1
Finally, we completely support the suggestion (11) that if
there is a reasonable chance of preventing SUDEP, it must
be discussed with patients with epilepsy who are at the
highest risk of SUDEP. With this goal in mind, the physician
can explain possible strategies that people with epilepsy and
their families can take to reduce their SUDEP risk. As all of
the risk factors, mechanisms, and specific methods to
prevent SUDEP are not yet completely understood, caution
remains prudent and necessary.
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